ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
As part of a review of its health-related businesses, the synthetic biology company Intrexon has consolidated all its health care assets and put them in a new subsidiary called Precigen. Through collaborations, joint ventures, and the start-up Xogenex, Intrexon’s synthetic biology technology is used in multiple gene- and cell-therapy candidates. Three clinical trials are under way, and up to 10 more could begin this year, the firm says. Separately, Intrexon President Geno Germano, who was hired from Pfizer less than a year ago as CEO-elect, has left the firm.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X